A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink

References

• EMA. Summary of opinion (initial authorisation). Eklira Genuair: aclidinium bromide. European Medicines Agency, Committee for Medicinal Products for Human Use; May 24, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002211/WC500127779.pdf. Accessed February 3, 2014.
   Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Global Initiative for Chronic Obstructive Lung Disease; 2020. Available from: http://goldcopd.org/gold-reports/. Accessed April 01, 2019.
   Google Scholar
• de Luise C, Lanes SF, Jacobsen J, Pedersen L, Sørensen HT. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol. 2007;22(4):267–272. doi:10.1007/s10654-007-9106-5
   PubMed Web of Science ®Google Scholar
• Jara M, Lanes SF, Wentworth C 3rd, May C, Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf. 2007;30(12):1151–1160. doi:10.2165/00002018-200730120-00007
   PubMed Web of Science ®Google Scholar
• Jara M, Wentworth C 3rd, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open. 2012;2(3):e000841. doi:10.1136/bmjopen-2012-000841
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008;3(1):163–169. doi:10.2147/COPD.S1516
   PubMedGoogle Scholar
• Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13–19. doi:10.1378/chest.08-2367
   PubMed Web of Science ®Google Scholar
• Verhamme KM, Afonso AS, van Noord C, et al. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther. 2012;25(1):19–26. doi:10.1016/j.pupt.2011.10.004
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Aguado J, Plana E, et al. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. 2019;152:37–43. doi:10.1016/j.rmed.2019.04.018
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766–768.
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy. 2003;23(5):686–689. doi:10.1592/phco.23.5.686.32205
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14. doi:10.1111/j.1365-2125.2009.03537.x
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Saczynski J, Andrade S, Harrold L, et al. Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(S1):129–140. doi:10.1002/pds.2313
   PubMedGoogle Scholar
• Rebordosa C, Plana E, Aguado J, et al. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019;28(2):126–133
   Google Scholar
• Saigi N, Rebordosa C, Bui C, et al. A validation exercise: identifying hospitalizations for heart failure among patients with COPD in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA [abstract]. Pharmacoepidemiol Drug Saf. 2019;28(S2):334.
   Google Scholar
• Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123:1964–1969. doi:10.1378/chest.123.6.1964
   PubMed Web of Science ®Google Scholar
• Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J. 2004;148:915–920. doi:10.1016/j.ahj.2004.03.048
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Wang D, Petrie MC, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010;12(6):557–565. doi:10.1093/eurjhf/hfq040
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5):1602245. doi:10.1183/13993003.02245-2016
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–1097. doi:10.1378/chest.09-2029
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events: a cohort analysis. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. a randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi:10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Andreas S, Taube C. Inhaled therapy reduces COPD mortality. ERJ Open Res. 2020;6(4):00634–2020. doi:10.1183/23120541.00634-2020
   PubMedGoogle Scholar
• Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):1801230. doi:10.1183/13993003.01230-2018
   PubMed Web of Science ®Google Scholar